VCBeat Health Contact Us
Home Gilead Reports Strong H1 2019 Results with Yescarta CAR-T Therapy Revenue Doubling to $216 Million

Gilead Reports Strong H1 2019 Results with Yescarta CAR-T Therapy Revenue Doubling to $216 Million

Jul 31, 2019 14:47 CST Updated 14:47
Gilead Sciences

Antiviral Drug Developer

On July 30, Gilead announced its financial results for the first half of 2019, with total revenue reaching $10.966 billion, a 2.1% increase. Revenue from the CAR-T therapy Yescarta doubled to $216 million.

Gilead’s Core Drug Sales Revenue in H1 2019 (USD billion)

Original Title: H1 2019, Gilead's Core Drug Sales Revenue! CAR-T Therapy Doubles

*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.